These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Mbhele N; Chimukangara B; Gordon M Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932 [TBL] [Abstract][Full Text] [Related]
43. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982 [TBL] [Abstract][Full Text] [Related]
44. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. Yang LL; Li Q; Zhou LB; Chen SQ Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480 [TBL] [Abstract][Full Text] [Related]
45. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA mBio; 2017 Apr; 8(2):. PubMed ID: 28377526 [TBL] [Abstract][Full Text] [Related]
46. Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients in Southeast China. Lai J; Liu Y; Han X; Huang A; Lin J; Ao W; Ye H; Chen Y Drug Des Devel Ther; 2021; 15():889-894. PubMed ID: 33679129 [TBL] [Abstract][Full Text] [Related]
47. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration. Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019 [TBL] [Abstract][Full Text] [Related]
48. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials. You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886 [TBL] [Abstract][Full Text] [Related]
49. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794 [TBL] [Abstract][Full Text] [Related]
50. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Pham HT; Mesplède T; Wainberg MA Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466 [TBL] [Abstract][Full Text] [Related]
52. Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients. Mbhele N; Gordon M J Biomol Struct Dyn; 2022; 40(23):12546-12556. PubMed ID: 34488561 [TBL] [Abstract][Full Text] [Related]
53. HIV-1 Group O Resistance Against Integrase Inhibitors. Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662 [TBL] [Abstract][Full Text] [Related]
54. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Yoshinaga T; Seki T; Miki S; Miyamoto T; Suyama-Kagitani A; Kawauchi-Miki S; Kobayashi M; Sato A; Stewart E; Underwood M; Fujiwara T Antiviral Res; 2018 Apr; 152():1-9. PubMed ID: 29410019 [TBL] [Abstract][Full Text] [Related]
55. Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors. Hikichi Y; Grover JR; Schäfer A; Mothes W; Freed EO Sci Adv; 2024 Mar; 10(9):eadn0042. PubMed ID: 38427738 [TBL] [Abstract][Full Text] [Related]
56. Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa. Brado D; Obasa AE; Ikomey GM; Cloete R; Singh K; Engelbrecht S; Neogi U; Jacobs GB Sci Rep; 2018 Mar; 8(1):4709. PubMed ID: 29549274 [TBL] [Abstract][Full Text] [Related]
57. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors. Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783 [TBL] [Abstract][Full Text] [Related]
58. Structural basis for strand-transfer inhibitor binding to HIV intasomes. Passos DO; Li M; Jóźwik IK; Zhao XZ; Santos-Martins D; Yang R; Smith SJ; Jeon Y; Forli S; Hughes SH; Burke TR; Craigie R; Lyumkis D Science; 2020 Feb; 367(6479):810-814. PubMed ID: 32001521 [TBL] [Abstract][Full Text] [Related]
59. HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. Zhao XZ; Smith SJ; Maskell DP; Metifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR ACS Chem Biol; 2016 Apr; 11(4):1074-81. PubMed ID: 26808478 [TBL] [Abstract][Full Text] [Related]
60. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Savarino A Retrovirology; 2007 Mar; 4():21. PubMed ID: 17374162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]